We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Have £5,000 to invest? I’d buy these 2 FTSE 100 growth stocks

These FTSE 100 growth stocks are beating the market. Roland Head explains why he expects these big-cap winners to deliver further gains.

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

The FTSE 100 is often associated with huge, mature businesses that pay dividends but deliver very little growth. Today I want to get away from that cliché and look at two terrific growth stocks that have made it into the blue-chip index.

Both of my picks have delivered double-digit share price gains over the last two years — the FTSE 100 has fallen by around 15% over the same period.

Should you buy Hikma Pharmaceuticals Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

Growth stock #1: a pharma play

Hikma Pharmaceuticals (LSE: HIK) has been a top performer so far this year, rising by around 20% in five months. Although pharmaceutical firms have benefited from extra investor interest due to the coronavirus pandemic, I believe Hikma is a genuine growth stock, with solid profits and good prospects.

The group’s business is centred around producing injectable medicines and generic versions of branded products that have lost their patent protection. It’s a very profitable business, with an operating margin of 24% in 2019.

Cash generation is also strong and unlike some larger pharma groups, Hikma doesn’t rely on borrowed cash. Net debt was just $242m at the end of 2019, giving a leverage multiple of just 0.4x EBITDA. In plain English, that’s very low.

Why I’d buy

City forecasts suggest that Hikma’s profits will rise by around 8% this year, with a 10% increase pencilled in for 2021.

The firm’s shares are currently trading close to all-time highs, leaving them with a 2020 forecast price/earnings ratio of around 18. That may not seem cheap, but it’s actually well below the UK pharmaceutical sector average P/E of 30.

Profits are expected to rise by a further 10% in 2021. I see the firm as a growth stock to buy at current levels.

Growth stock #2: my bet on UK property

The UK housing market might not seem like the safest investment at the moment. But I think my next pick is an essential service that estate agents can’t live without — even in a downturn.

Property listing website Rightmove (LSE: RMV) dominates the UK market, leaving rivals Zoopla and OnTheMarket.com trailing in the distance. According to the firm, it had a market share of over 75% in 2019, based on the time spent browsing the top four UK property websites.

This dominance gives Rightmove a lot of pricing power. The company generated an operating profit of £214m on revenue of £289m last year. That’s equivalent to a profit margin of 74%. It’s not hard to see why this has been such a successful growth stock — the Rightmove share price has risen by nearly 40% over the last 18 months.

A long-term winner?

Estate agents tend to complain about Rightmove’s pricing. Some big estate agency groups even clubbed together to launch a rival, OnTheMarket.com.

I have some sympathy with the estate agents’ complaints. But Rightmove is expanding steadily into the letting sector and now also lists new homes. In reality, I believe this website will continue to be an essential part of most estate agents’ businesses.

Rightmove has cut its fees by 75% for the period from April to July this year. 2020 profits will be down. But analysts expect earnings to bounce back next year — a view I share.

The latest forecasts put Rightmove stock on a price/earnings ratio of 30 for 2021. For such a dominant and profitable business, I think this could be a good buy.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals and Rightmove. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

British pound data
Investing Articles

What’s your plan for a stock market crash?

The stock market might be flying, but the time to think about a crash is before it happens. Fortunately, it…

Read more »

Investing Articles

Will SpaceX stock explode on entry?

The SpaceX IPO is just days away and excitement about the stock has gone into orbit. Harvey Jones is urging…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

CMC Markets: a FTSE dividend star worth considering for an ISA or SIPP?

This FTSE dividend stock doesn’t get a lot of attention. But things are starting to change as it’s posting brilliant…

Read more »

British coins and bank notes scattered on a surface
Investing Articles

Income investors love insurance stocks. Here’s my top pick from the FTSE 100

High dividend yields often make insurance stocks attractive for passive income investors. But which is Stephen Wright’s top choice?

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

See what £10,000 invested in dismal Diageo shares just 1 week ago is worth today

Diageo shares are all hangover and no fizz, says Harvey Jones. How long must investors wait before the FTSE 100…

Read more »

Rear view image depicting a senior man in his 70s sitting on a bench leading down to the iconic Seven Sisters cliffs on the coastline of East Sussex, UK. The man is wearing casual clothing - blue denim jeans, a red checked shirt, navy blue gilet. The man is having a rest from hiking and his hiking pole is leaning up against the bench.
Investing Articles

Up 1,146%! 7 things I’ve learned from the stunning Rolls-Royce share price comeback 

Harvey Jones has made a fair bit of money out of the booming Rolls-Royce share price, but he's also learned…

Read more »

Golden Retirees Heading to Beach
Investing Articles

4 steps to building a £38,456 retirement income with ISA shares

Investing £300 a month could deliver a life-changing cash stream in retirement with high-yield income shares. Royston Wild explains how.

Read more »

Content white businesswoman being congratulated by colleagues at her retirement party
Investing Articles

How investing in a Cash ISA could cost you a comfortable retirement

Cash ISAs are celebrated for the brilliant tax benefits they provide. But could focusing on them cost savers the chance…

Read more »